Navigant’s Pathogen Inactivation System Will Compete On Price, Ease Of Use
This article was originally published in The Gray Sheet
Executive SummaryNavigant Biotechnologies CEO Teresa Ayers' first priority as head of the Gambro subsidiary will be to raise funds to commercialize its blood pathogen reduction technology
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.